Abaloparatide
approvedAlso known as: Tymlos, BA058
**Mechanism of Action** Abaloparatide is a synthetic analog of parathyroid hormone-related protein (PTHrP(1-34)) that acts as a selective agonist at the PTH1 receptor. Unlike teriparatide (PTH(1-34)), which activates both Gs/cAMP and β-arrestin signaling pathways, abaloparatide preferentially stimulates the Gs/cAMP pathway while inducing weaker β-arrestin recruitment. This biased signaling reduces receptor desensitization and internalization, leading to prolonged anabolic effects on bone formation with minimal stimulation of bone resorption. The net result is increased trabecular and cortical bone mass, improved bone microarchitecture, and enhanced bone strength, with a lower incidence of hypercalcemia compared to teriparatide. **Key Research Findings** The pivotal phase III ACTIVE trial (NCT01343004) demonstrated that abaloparatide significantly reduced vertebral (86% reduction) and nonvertebral (43% reduction) fracture risk over 18 months in postmenopausal women with osteoporosis, compared to placebo. Bone mineral density (BMD) gains at the lumbar spine (11.2%), total hip (4.3%), and femoral neck (4.2%) were superior to both placebo and teriparatide. A subsequent extension study (ACTIVExtend) showed sustained fracture risk reduction and BMD improvements when abaloparatide was followed by alendronate. Preclinical studies confirmed its ability to stimulate periosteal bone formation and improve cortical geometry, while clinical pharmacokinetic data indicate rapid absorption (Tmax ~0.5 h) and a short half-life (~1.7 h), consistent with daily subcutaneous dosing. **Clinical Relevance** Abaloparatide is FDA-approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture, including those with a history of osteoporotic fracture, multiple risk factors, or failure/intolerance to other therapies. Its favorable safety profile—particularly lower hypercalcemia rates (3.4% vs. 6.4% with teriparatide)—and robust anabolic efficacy position it as a first-line bone-forming agent. Treatment is limited to 2 years due to potential osteosarcoma risk observed in rat studies (though not confirmed in humans). It is contraindicated in patients with Paget’s disease, unexplained alkaline phosphatase elevations, or prior radiation therapy involving the skeleton. For research purposes only — not medical advice.
Key data
C174H300N56O49Research & studies
Many osteoporosis patients remain undiagnosed and untreated.; Current therapies include antiresorptive (bisphosphonates, denosumab, raloxifene) and osteoanabolic (teriparatide, abaloparatide, romosozumab) agents.; Sequential therapies and goal-directed individualized strategies are recommended for long-term management.; New treatments under investigation show promise for improving bone health.
Osteoporosis affects 1 in 3 women and 1 in 5 men over 50 worldwide.; Risk factors include older age, female sex, prior fractures, glucocorticoid use, and low BMD.; Antiresorptive agents reduce vertebral fractures by 52 per 1000 person-years and hip fractures by 6 per 1000 person-years.; Fracture liaison services increase medication initiation and adherence from 17% to 38%.
Teriparatide, abaloparatide, and romosozumab are osteoanabolic agents that reduce fracture risk in patients with severe low bone mass or prior vertebral/hip fractures.; These agents show superior enhancement of bone mineral density and fracture reduction compared to traditional bisphosphonate therapies.; Each medication has unique characteristics, distinct efficacy profiles, and specific adverse effects that require careful consideration.; Clinical use involves evaluating economic factors, injection frequency, and potential adverse effects for informed treatment decisions.
AFFs are associated with 3-5 years of antiresorptive medication use.; A visible transverse line in the lateral cortex ('dreaded black line') is a key diagnostic feature.; Prodromal pain in hip, groin, thigh, or knee occurs in over half of cases and is often misdiagnosed.; Intramedullary nailing is indicated for complete fractures and incomplete fractures with a visible fracture line.
Osteoporosis prevalence is 10.2% in adults >50, projected to rise to 13.6% by 2030.; Screening with DXA is recommended for women ≥65 and postmenopausal women with risk factors; men ≥70 or with risk factors per Bone Health and Osteoporosis Foundation.; Diagnosis requires T-score ≤ -2.5 or presence of fragility fracture.; High-risk patients may use antiresorptive drugs (bisphosphonates, denosumab); very high risk or prior vertebral fracture may require anabolic agents (teriparatide, abaloparatide, romosozumab).
Bisphosphonates and denosumab reduced hip, clinical and radiographic vertebral, and other clinical fractures in postmenopausal females with osteoporosis (moderate to high CoE).; Bisphosphonates for 36 months or more may increase the risk for atypical femoral fractures and osteonecrosis of the jaw, but absolute risks were low.; Abaloparatide and teriparatide reduced clinical and radiographic vertebral fractures but increased the risk for withdrawals due to adverse events.; Few studies examined participants with low bone mass, males, or Black-identifying persons, sequential therapy, or treatment beyond 3 years.
Frequently asked questions
What is Abaloparatide?
**Mechanism of Action** Abaloparatide is a synthetic analog of parathyroid hormone-related protein (PTHrP(1-34)) that acts as a selective agonist at the PTH1 receptor. Unlike teriparatide (PTH(1-34)), which activates both Gs/cAMP and β-arrestin signaling pathways, abaloparatide preferentially stimulates the Gs/cAMP pat
How does Abaloparatide work?
PTHrP(1-34) analog that selectively favors bone anabolism with less hypercalcemia than teriparatide; approved for osteoporosis.
What is the research status of Abaloparatide?
Abaloparatide is currently classified as approved, with 389 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of Abaloparatide?
Abaloparatide has a molecular weight of approximately 3961 g/mol (formula C174H300N56O49).
Related peptides
Long-acting somatostatin analog that inhibits GH, glucagon, and gut hormone secretion; used for acromegaly and neuroendocrine tumors.
Recombinant PTH(1-34) that, given intermittently, stimulates osteoblastic bone formation; approved for severe osteoporosis.
Depot somatostatin analog inhibiting GH/IGF-1 and neuroendocrine secretion; approved for acromegaly and GEP-NETs.
36-aa HIV gp41 fusion inhibitor that blocks viral entry into CD4 cells; first-in-class antiretroviral fusion inhibitor.
Selective bradykinin B2 receptor antagonist decapeptide approved for acute attacks of hereditary angioedema.
Build on Abaloparatide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key